Device Trial Radar · NCT07925008
Clinical Study on the Safety and the Performance of an Endometrial Ablation System in Women With Abnormal Uterine Bleeding (AUB) and Previous Cesarean Delivery
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Aqua Therapeutics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 30 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Abnormal uterine bleeding (AUB) is defined as "flow outside of normal volume, duration, regularity, or frequency". Acute AUB is excessive bleeding that requires immediate intervention to prevent further blood loss. Chronic AUB refers to irregularities in menstrual bleeding for most of the previous 6 months. AUB can be frequent or infrequent, prolonged, irregular, or heavy. Heavy menstrual bleeding (HMB) is defined as "excessive menstrual blood loss which interferes with a woman's physical, social, emotional and/or material quality of life". Causes of AUB are classified as polyps, adenomyosis, leiomyomas (AUB-L), malignancy and premalignant conditions, coagulopathy, ovulatory disorders (AUB-O), endometrial disorders (AUB-E), iatrogenic, and 'not classified ' . AUB affects approximately one in four women between 30 and 50 years of age, with serious implications on woman's quality of life (QoL). Endometrial ablation (EA) is a uterus-preserving procedure that aims to destroy or remove the endometrial tissue in selected women who have no desire for future fertility. EA has become an alternative to hysterectomy in the treatment of AUB because it is less invasive and has a shorter recovery period. At present, many different techniques are available to remove the endometrial tissue. Resectoscopic endometrial ablation (REA) consists of targeted endometrial destruction under direct hysteroscopic visualization. REA techniques include endometrial laser ablation, transcervical resection of the endometrium, and rollerball endometrial ablation. Non-resectoscopic endometrial ablation (NREA) uses a variety of energy sources to non-selectively destroy the endometrial lining and include thermal balloon endometrial ablation, microwave endometrial ablation, hydrothermal ablation, bipolar radiofrequency endometrial ablation, endometrial cryotherapy, and more recently vapor endometrial ablation. NREA technologies require short surgical time and can also be performed in the outpatient setting. Vapor EA is one of the newest approaches in the field. In this context, the Aqua Therapeutics Thermal Therapy Vapor Ablation system (ATTTVAS; AQUA Therapeutics Inc.) is a novel system designed to ablate uterine tissue using vapor thermal therapy technology. The ATTTVAS is indicated to ablate the endometrial lining of the uterus in premenopausal women with abnormal uterine bleeding (AUB) due to benign causes for whom childbearing is complete. In this Pre-Market, Traditional Feasibility, Pilot, Interventional, Clinical Investigation we aim to evaluate the Safety and the Performance of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) In Premenopausal Women with Abnormal Uterine Bleeding (AUB) and a History of Cesarean Section.
Conditions
- Menorrhagia
Interventions
Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS)Device
The Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) is indicated to ablate the endometrial lining of the uterus in premenopausal women with abnormal uterine bleeding (AUB) due to benign causes for whom childbearing is complete. The ATTTVAS is intended to be used by qualified healthcare professionals specifically trained in the field of endometrial ablation. The ATTTVAS is intended for outpatient use although it can easily be utilized in both a surgery centre and the operating room as well
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety will be monitored through the reporting of the adverse events, serious adverse events and concomitant medications during the entire study duration.Time frame: V-1(within40 days before baseline);V0 (baseline); V1 (day 2, EndoAblation_discharge)V2(phone call 24 hours after discharge);V3(1week after V1)V4(6 weeks afterV1);unscheduled visit (betweenV2 andV5);V5(12weeksAfterDischarge)
- To evaluate the safety of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS). Safety will be monitored through vital sign.Time frame: V1 (day 2, Endometrial ablation) and unscheduled visit that could be taken between phone call 24 hours after discharge and 12weeksAfterDischarge
- To evaluate the safety of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS). Safety will be monitored through vital signs.Time frame: V1 (day 2, Endometrial ablation) and unscheduled visit that could be taken between phone call 24 hours after discharge and 12weeksAfterDischarge
3 more outcomes with a free account
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Akademisches Lehrkrankenhaus Feldkirch
Feldkirch, Austria · Recruiting
U.O.C. Ginecologia Oncologica
Roma, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.